MCI-030 / ADT Pharma, ChemomAb - LARVOL DELTA

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer. (PubMed, J Ovarian Res) - "Using small molecule inhibitors, Pf-2545920 and a novel NSAID-derived PDE10A inhibitor, MCI-030, we show that PDE10A inhibition leads to decreased ovarian cancer cell growth and induces cell cycle arrest and apoptosis...We also demonstrate that PDE10A inhibition leads to decreased Wnt-induced β-catenin nuclear translocation, as well as decreased EGF-mediated activation of RAS/MAPK and AKT pathways in ovarian cancer cells. These findings implicate PDE10A as novel target for ovarian cancer chemoprevention and treatment."

Journal • Immunology • Inflammation • Oncology • Ovarian Cancer • Solid Tumor • EGF • LINC00473

[VIRTUAL] PDE10A as a novel target to suppress Wnt/β-catenin signaling and other oncogenic pathways in ovarian cancer (AACR 2021) - "This study evaluates the effects of phosphodiesterase 10A (PDE10A) inhibition as a novel chemopreventive and therapeutic approach for ovarian cancer. We investigated the effects of PDE10A small molecule inhibitors, Pf-2545920 and MCI-030 (a novel non-COX inhibitory NSAID-derivative), and PDE10A knockout by CRISPR/Cas9 gene editing in various ovarian cancer cell lines using in vitro assays that measured cell proliferation, cell viability, cell cycle arrest, apoptosis, cell migration and invasion... Our data demonstrate that PDE10A has pro-tumorigenic effects in ovarian cancer cells and its high expression in ovarian cancer patients is associated with poor prognosis. Altogether, our results warrant future studies of PDE10A as a novel target for ovarian cancer chemoprevention and/or treatment."

Oncology • Ovarian Cancer • Solid Tumor • EGF • TGFB1

[VIRTUAL] The novel NSAID-derivative, MCI-030, prevents ovarian cancer in the egg-laying hen by increasing tumor cell apoptosis and decreasing beta-catenin and MAPK oncogenic signaling (SGO 2021) - No abstract available

Oncology • Ovarian Cancer • Solid Tumor

Anchiano Therapeutics reports year-end 2019 financial results (GlobeNewswire) - "Entered into an exclusive worldwide collaboration and option to license agreement on September 20, 2019 with ADT Pharmaceuticals, LLC ('ADT') to develop novel small-molecule pan-RAS inhibitors and PDE10/β-catenin inhibitors...Announced the discontinuation of Anchiano’s Phase 2 Codex study evaluating the gene therapy inodiftagene vixteplasmid in patients with BCG-unresponsive non-muscle-invasive bladder cancer..."

Licensing / partnership • Trial termination